Fluticasone Propionate

證據等級: L5

預測適應症: 10 個

Fluticasone Propionate: From Established Corticosteroid Therapy to Atopic Dermatitis

Note on indication selection: Fluticasone propionate has 10 TxGNN-predicted indications in this evidence pack. The single highest-scoring candidate (“2-hydroxyethyl methacrylate sensitization”, 98.56%) has zero supporting trials or literature (Evidence Level L5, Hold). This report instead focuses on Atopic Dermatitis, the candidate with by far the strongest evidence base (8 relevant clinical trials, 10 relevant publications; L1, decision-stage S3, “Proceed with Guardrails”) among the candidates evaluated.

One-Sentence Summary

Fluticasone propionate is a topical corticosteroid; its original indication is not documented in this evidence pack (no local regulatory licences on file). The TxGNN model’s best-evidenced prediction for this drug is Atopic Dermatitis, supported by 8 clinical trials (mostly completed Phase 4 RCTs) and 10 relevant publications. Notably, the evidence itself indicates fluticasone is already a well-established topical treatment for atopic dermatitis internationally — so this largely confirms existing standard-of-care use rather than a genuinely novel indication, and the practical question is local market registration rather than new clinical development.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (no regulatory licences on file)
Predicted New Indication	Atopic Dermatitis
TxGNN Prediction Score	95.32%
Evidence Level	L1 (multiple completed Phase 4 RCTs plus a dedicated RCT publication)
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data (e.g. a DrugBank MOA record) is not available for fluticasone propionate in this evidence pack. Based on the repurposing rationale accompanying this candidate, fluticasone propionate is a classic topical corticosteroid that acts by suppressing release of inflammatory mediators and reducing inflammation in the stratum corneum — a mechanism well matched to atopic dermatitis, which is itself an inflammatory skin condition.

Importantly, the evidence pack’s own rationale flags that atopic dermatitis is “one of its already widely used core indications” for fluticasone propionate — i.e., this is not a genuinely novel repurposing target, but an existing, extensively documented standard treatment (marketed internationally as products such as Cutivate). This is reflected in the evidence: multiple completed Phase 4 (post-marketing) RCTs and a dedicated placebo/vehicle-controlled RCT support efficacy and safety in both paediatric and adult populations.

The practical value of this candidate is therefore less about establishing a new clinical hypothesis and more about local market status: this evidence pack shows zero local regulatory licences and a “not marketed” status, meaning the opportunity is one of registration/availability in this jurisdiction rather than new indication research.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00546000	Phase 4	Completed	56	Open-label study of Cutivate (fluticasone propionate) lotion 0.05% on HPA-axis effects in infants/children with atopic dermatitis
NCT00689832	Phase 4	Completed	487	Double-blind RCT: tacrolimus 0.03% vs fluticasone 0.005% ointment in children ≥2 years with moderate-to-severe atopic dermatitis
NCT00690105	Phase 4	Completed	577	Double-blind RCT: tacrolimus 0.1% vs fluticasone 0.005% ointment in adults with facial (“red face”) atopic dermatitis
NCT00616538	Phase 4	Completed	121	Randomised pilot comparing EpiCeram device vs mid-strength fluticasone propionate 0.05% in paediatric atopic dermatitis
NCT01915914	Phase 4	Completed	107	Randomised open-label study of intermittent (twice-weekly) fluticasone 0.05% cream to reduce relapse risk in stabilised paediatric atopic dermatitis
NCT00119158	Phase 4	Completed	90	Double-blind, vehicle-controlled study of pimecrolimus (Elidel) plus fluticasone (Cutivate) combination vs monotherapy in severe atopic dermatitis
NCT03742414	Phase 2	Active, not recruiting	398	Randomised controlled “SEAL” study of proactive skin-barrier care plus fluticasone propionate cream to reduce AD severity and prevent food allergy in infants
NCT01772056	Phase 3	Terminated	54	RCT of twice-weekly fluticasone propionate 0.05% cream maintenance therapy to reduce relapse in children with mild/moderate AD (terminated before completion)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29373242	2018	RCT	Allergologia et immunopathologia	Intermittent fluticasone propionate 0.05% cream dosing reduced relapse risk vs vehicle in children with stabilised AD
21977914	2012	Review	J Eur Acad Dermatol Venereol	Fluticasone propionate has a favourable benefit/risk ratio and high therapeutic index for both intervention and maintenance treatment of AD
15608497	2005	Review	Skin Pharmacol Physiol	Reviews safety and efficacy of fluticasone propionate cream/ointment across dermatological disorders including AD, psoriasis and vitiligo
32555122	2020	Review	The Medical Letter on Drugs and Therapeutics	Independent drug-class review of therapies for atopic dermatitis, including topical corticosteroids
33150035	2020	Cohort	Dermatol Pract Concept	Open-label prospective study comparing topical fluticasone vs tacrolimus in proactive AD treatment
11862174	2002	Cohort	J Am Acad Dermatol	Established safety of fluticasone propionate cream 0.05% in severe/extensive AD in infants as young as 3 months
27543211	2016	Cohort	J Am Acad Dermatol	Fluticasone propionate cream plus bleach baths reduced S. aureus skin colonisation in childhood AD
12207596	2002	Clinical study	Br J Dermatol	Intermittent dosing of fluticasone propionate cream reduced relapse risk in AD patients
14522623	2003	Clinical study	J Dermatolog Treat	Two comparative multicentre RCTs of fluticasone propionate 0.05% cream for acute and maintenance treatment of AD in children
41730175	2026	Review	The Medical Letter on Drugs and Therapeutics	Updated independent review of AD drug therapies

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 4 RCTs plus a dedicated placebo/vehicle-controlled RCT support the efficacy and established safety profile of topical fluticasone propionate in atopic dermatitis — this is a well-characterised, internationally standard use, not an untested hypothesis. However, this evidence pack shows no local regulatory licences on file and is missing MOA and PI-level safety data, so the practical path forward (registration status, local safety labelling) needs direct confirmation.

To proceed, the following is needed:

Independently verify current TGA/ARTG registration status (this evidence pack shows 0 licences, which should be checked against the live ARTG database)
Obtain the TGA-approved Product Information for warnings, contraindications and drug interactions
Obtain DrugBank/manufacturer mechanism-of-action documentation
Clarify whether this represents a genuine new market-entry opportunity or an existing unlisted product
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.